Literature DB >> 6314884

Pharmacokinetics of ceftizoxime in subjects with various degrees of renal function.

S F Kowalsky, R M Echols, A R Venezia, E A Andrews.   

Abstract

The pharmacokinetics of ceftizoxime (FK-749) were studied in 20 volunteers with various degrees of renal function. Creatinine clearances ranged from zero to 157 ml/min per 1.73 m2. One gram of ceftizoxime was administered by a 30-min drip infusion, and blood and urine samples were collected for up to 48 h after drug administration. For volunteers with a creatinine clearance of greater than or equal to 80 ml/min per 1.73 m2 (group I), the mean half-life was 1.65 h, whereas for volunteers with a creatinine clearance of less than 10 ml/min per 1.73 m2 (group IV), the half-life was 34.7 h. The volume of distribution at steady state (Vdss) and the volume of distribution area (Vdarea) were calculated for each group and ranged from 0.377 to 0.263 and 0.421 to 0.264 liters/kg for groups I and IV, respectively. Total body clearance of ceftizoxime correlated with creatinine clearance (r = 0.953), and the mean urinary recovery of unchanged drug in normal volunteers was 72.4%. A 4-h hemodialysis procedure reduced serum ceftizoxime concentrations by approximately 52%; however, serum concentrations at 48 h after drug administration were still greater than 10 micrograms/ml in dialysis subjects. By using the relationship between total body clearance of ceftizoxime and creatinine clearance, a nomogram was developed to assist in the administration of ceftizoxime to patients with renal dysfunction.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6314884      PMCID: PMC185129          DOI: 10.1128/AAC.24.2.151

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  4 in total

1.  Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data.

Authors:  J G Wagner
Journal:  J Pharmacokinet Biopharm       Date:  1976-10

2.  Pharmacology of cefazolin in patients with normal and abnormal renal function.

Authors:  M E Levison; S P Levison; K Ries; D Kaye
Journal:  J Infect Dis       Date:  1973-10       Impact factor: 5.226

3.  Pharmacokinetic data. Pharmacokinetic parameters estimated from intravenous data by uniform methods and some of their uses.

Authors:  J G Wagner
Journal:  J Pharmacokinet Biopharm       Date:  1977-04

4.  Pharmacology of ceftizoxime compared with that of cefamandole.

Authors:  H C Neu; S Srinivasan
Journal:  Antimicrob Agents Chemother       Date:  1981-09       Impact factor: 5.191

  4 in total
  6 in total

1.  Liquid chromatographic assay of ceftizoxime in sera of normal and uremic patients.

Authors:  E M McCormick; R M Echols; T G Rosano
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

Review 2.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

Review 3.  A retrospective analysis of pharmacokinetic-pharmacodynamic parameters as indicators of the clinical efficacy of ceftizoxime.

Authors:  A Sánchez-Navarro; C I Colino; M M Sánchez Recio
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

4.  Assessment of serum bactericidal activity after administration of cefoperazone, cefotaxime, ceftizoxime, and moxalactam to healthy subjects.

Authors:  S L Barriere; D C Ozasa; J Mordenti
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

Review 5.  Clinical pharmacokinetics of the third generation cephalosporins.

Authors:  L Balant; P Dayer; R Auckenthaler
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

Review 6.  Ceftizoxime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Richards; R C Heel
Journal:  Drugs       Date:  1985-04       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.